ZELLUNA ASA (ZLNA.OL) Stock Price, Forecast & Analysis
Europe - OSL:ZLNA - NO0013524942 - Common Stock
ZLNA.OL Key Statistics, Chart & Performance
The current stock price of ZLNA.OL is 9.89 NOK. In the past month the price decreased by -11.74%.
ZLNA.OL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 69.42 | 45.91B | ||
| ARGX.BR | ARGENX SE | 71.47 | 47.26B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 22.76B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.01B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.25B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.86B | ||
| 5CV.DE | CUREVAC NV | 5.19 | 1.02B | ||
| NANO.PA | NANOBIOTIX | N/A | 872.70M | ||
| PHIL.MI | PHILOGEN SPA | 21.05 | 701.76M | ||
| IVA.PA | INVENTIVA SA | N/A | 480.61M | ||
| FYB.DE | FORMYCON AG | N/A | 379.02M | ||
| ALCLS.PA | CELLECTIS | N/A | 328.57M |
Related stock screener links
About ZLNA.OL
Company Profile
Zelluna ASA is a biotechnology company focused on developing innovative and cost-efficient therapies for advanced solid cancers. The company is headquartered in Oslo, Oslo and currently employs 26 full-time employees. The company went IPO on 2019-06-03. The firm develops cell therapies for the treatment of cancer patients. Zelluna ASA deals with eliminate solid cancers by unleashing thel elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies. The firm provides benefit to patients, their families and all those around them, by developing therapies that bring together TCR guidance with the effector functions of allogeneic NK cells (TCR-NK) deploying a mechanism of action that has the potential to be both safe and potent. Zelluna ASA operates worldwide.
Company Info
ZELLUNA ASA
Ullernchausseen 64
Oslo OSLO NO
Employees: 26
Phone: 4741380080
ZELLUNA ASA / ZLNA.OL FAQ
What does ZELLUNA ASA do?
Zelluna ASA is a biotechnology company focused on developing innovative and cost-efficient therapies for advanced solid cancers. The company is headquartered in Oslo, Oslo and currently employs 26 full-time employees. The company went IPO on 2019-06-03. The firm develops cell therapies for the treatment of cancer patients. Zelluna ASA deals with eliminate solid cancers by unleashing thel elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies. The firm provides benefit to patients, their families and all those around them, by developing therapies that bring together TCR guidance with the effector functions of allogeneic NK cells (TCR-NK) deploying a mechanism of action that has the potential to be both safe and potent. Zelluna ASA operates worldwide.
What is the current price of ZLNA stock?
The current stock price of ZLNA.OL is 9.89 NOK. The price increased by 0.95% in the last trading session.
Does ZLNA stock pay dividends?
ZLNA.OL does not pay a dividend.
What is the ChartMill rating of ZELLUNA ASA stock?
ZLNA.OL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for ZLNA.OL stock?
9 analysts have analysed ZLNA.OL and the average price target is 25.5 NOK. This implies a price increase of 157.84% is expected in the next year compared to the current price of 9.89.
Should I buy ZLNA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ZLNA.OL.
Can you provide the ownership details for ZLNA stock?
You can find the ownership structure of ZELLUNA ASA (ZLNA.OL) on the Ownership tab.
ZLNA.OL Technical Analysis
ZLNA.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ZLNA.OL. While ZLNA.OL has a great health rating, there are worries on its profitability.
ZLNA.OL Financial Highlights
Over the last trailing twelve months ZLNA.OL reported a non-GAAP Earnings per Share(EPS) of -44.31. The EPS increased by 14.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -170.55% | ||
| ROE | -213.94% | ||
| Debt/Equity | 0 |
ZLNA.OL Forecast & Estimates
9 analysts have analysed ZLNA.OL and the average price target is 25.5 NOK. This implies a price increase of 157.84% is expected in the next year compared to the current price of 9.89.